Baricitinib (Olumiant): Janus kinase (JAK) inhibitor which blocks subtypes JAK1. JAK3 and to a lesser extent JAK2.
True
False
Baricitinib (Olumiant):
Second-line treatment for moderate/severe adult rheumatoid arthritis either as monotherapy or with methotrexate. (European Union)
Approved for adults exhibiting moderately-severe active rheumatoid arthritis without prior effective response to one or more TNF antagonist treatments
Both
Neither
Baricitinib (Olumiant) classified as:
Targeted, synthetic small-molecule (tsDMARD)
A JAK inhibitor and an inhibitor of the JAK-STAT signaling pathway
Both
Neither
Baricitinib (Olumiant): In 2020, baricitinib was granted emergency use authorization for use in combination with remdesivir for COVID 19 treatment in hospitalized patients requiring supplemental oxygen, ECMO or invasive mechanical ventilation. [ECMO: extracorporeal membrane oxygenation]
True
False
Baricitinib (Olumiant): Off label baricitinib use with topical corticosteroids:
Improvement in severe atopic dermatitis
Baricitinib alone used in treating psoriatic arthritis and vitiligo.
Both
Neither
Baricitinib (Olumiant): Common side effect(s):
Cold sores
Cold symptoms
Both
Neither
Baricitinib (Olumiant): Pharmacokinetics
Bioavailability is about 80%.
Elimination half-life is about 12 hours
Both
Neither
Baricitinib (Olumiant):
Pharmacokinetics:
True
False
Probenecid, an inhibitor of the organic anion transporter-3, when administered along with baricitinib causes the doubling of baricitinib blood levels. Patients taking baricitinib along with probenecid
will likely require reduction in baricitinib dose.
Rothlin C Gutkind J Chapter 39
Immunosuppressants, Immunomodulation and Tolerance In
Goodman & Gilman's The Pharmacological Basis of Therapeutics
(Brunton LL Knollman BC eds) McGraw Hill LLC (2023).
Lake
D & Briggs A Ch 55 Immunopharmacology in Katzung's Basic &
Clinical Pharmacology (Vanderah TW, ed) 16e McGraw Hill
2023.
Kafaja T Anwar S Furst D Ch 36 Non
Steroidal Anti-Inflammatory Drugs, Disease-Modifiying
Antirheumatic Drugs, Nonopioid Analgesics, & Drugs Used in
Gout Katzung's Basic & Clinical Pharmacology (Vanderah TW,
ed) 16e McGraw Hill 2023.
Brezinski E Klickstein L Armstrong A Ch 46 Pharmacology of Immunosuppression in Principles of Pharmacology: The
Pathophysiologic Basis of Drug Therapy. (Golan DE Armstrong
EJ Armstrong AW, eds) 4e 2017
Ritter JM Flower R
Henderson G Loke YK MacEwan D Robinson E Fullerton J Ch 25
Anti-inflammatory and Immunosuppressant Drugs Rang & Dale's
Pharmacology 10e Elsevier 2024.
Burchum J Rosenthal L
Lehne's Pharmacology for Nursing Care Ch 72
Immunosuppressants Elsevier 2022.
Burchum J Rosenthal L
Lehne's Pharmacology for Nursing Care Ch 75 Glucocorticoids
in Nonendrocrine Disorders Elsevier 2022.
Burchum J Rosenthal L
Lehne's Pharmacology for Nursing Care Ch 76 Drug Therapy for
Rheumatoid Arthritis Elsevier 2022.
Bass A Rogatsky Ch 32
Immunomodulatory Drugs in Goldman-Cecil Medicine (Goldman L
Schafer, eds) Elsevier 26e 2020
Leiva M Takemoto Ch
238 Immunosuppressants in Lippincott Illustrated Reviews:
Pharmacology 8e ((Walen et al, eds) Wolters Kluwer 2023.
Hall J Hall M Ch 78
Adrenocortical Hormones Guyton and Hall Textbook of Medical
Physiology 14e Elsevier 2021.
Waller DG Sampson A
Hitchings Ch 38 The Immune Response and Immunosuppressant
Drugs Medical Pharmacology & Therapeutics 6e Elsevier
2022
Waller DG Sampson A
Hitchings Ch 30 Rheumotoid Arthritis, Other Inflammatory
Arthrides and Osteoarthritis Medical Pharmacology &
Therapeutics 6e Elsevier 2022